Biotech CSL NPAT rises 11%

Biotech CSL NPAT rises 11%

  Biotech CSL (ASX:CSL) report their Net Profit After Tax US$1.9 billion up 11 per cent on the prior corresponding period US$1.7 billion. The company has seen increased demand for its blood-based therapies – immunoglobulin and albumin therapies. Seasonal flu vaccine sales also increased in demand. Total revenue $8.5 billion from last year’s $7.9 billion. Final dividend was a rise on last year’s 93 US cents to US$1:00. Shares in CSL (ASX:CSL) are trading 6.8 per cent higher at $234.42 Copyright 2019 – Finance News Network Source: Finance News Network

Share this post